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ABSTRACT
Objectives To evaluate maintenance of response while
reducing intravenous abatacept dose from ∼10 mg/kg to
∼5 mg/kg in patients with early rheumatoid arthritis
(RA) who achieved disease activity score (DAS)28
(erythrocyte sedimentation rate, ESR) <2.6.
Methods This 1-year, multinational, randomised,
double-blind substudy evaluated the efficacy and safety
of ∼10 mg/kg and ∼5 mg/kg abatacept in patients with
early RA with poor prognosis who had reached DAS28
(ESR) <2.6 at year 2 of the AGREE study. The primary
outcome was time to disease relapse (defined as
additional disease-modifying antirheumatic drugs, ≥2
courses high-dose steroids, return to open-label
abatacept ∼10 mg/kg, or DAS28 (C reactive protein)
≥3.2 at two consecutive visits).
Results 108 patients were randomised (∼10 mg/kg,
n=58; ∼5 mg/kg, n=50). Three and five patients,
respectively, discontinued, and four per group returned to
open-label abatacept. Relapse over time and the proportion
of patients relapsing were similar in both groups (31%
(∼10 mg/kg) vs 34% (∼5 mg/kg); HR: 0.87 (95% CI 0.45
to 1.69)). Mean steady-state trough serum concentration for
the ∼10 mg/kg group was 20.3–24.1 mg/mL, compared
with 8.8–12.0 mg/mL for the ∼5 mg/kg group.
Conclusions This exploratory study suggests that
abatacept dose reduction may be an option in patients with
poor prognosis early RA who achieve DAS28 (ESR) <2.6
after ≥1 year on abatacept (∼10 mg/kg).
Trial registration number NCT00989235.
INTRODUCTION
Current recommendations support the use of bio-
logical disease-modifying antirheumatic drugs
(DMARDs) in combination with methotrexate
(MTX) in patients with rheumatoid arthritis (RA)
who have responded insufficiently to conventional
synthetic DMARDs.1 2 However, studies in
DMARD-naïve patients with early RA have demon-
strated the superiority of biological DMARDs plus
MTX compared with MTX alone,3–6 especially in
patients at high risk of progression of structural
damage. This creates a challenge for the rheuma-
tologist, concerning the appropriate use of biolo-
gics while maximising cost-effectiveness and
therapeutic benefit.7
Drug-free remission remains a therapeutic goal in
RA. In established RA, withdrawal of biological
therapy generally leads to loss of remission for the
majority of patients.8 9 However, dose reduction is
a feasible strategy for some patients as shown in the
PRESERVE study.10 In early RA, withdrawal of bio-
logical treatment is possible.11–13 However, with-
drawal of all therapies is less successful.14 15 In
early RA, dose reduction is possible for the large
majority of patients.14
There is also evidence that early biological inter-
vention may alter the course of RA. In the ADJUST
(Abatacept study to Determine the effectiveness in
preventing the development of rheumatoid arthritis
in patients with Undifferentiated inflammatory arth-
ritis and to evaluate Safety and Tolerability) study,
26 patients with undifferentiated arthritis or early
RA (American College of Rheumatology 1987 cri-
teria)16 received intravenous abatacept monotherapy
(∼10 mg/kg) or placebo for 6 months. Progression
to RA was delayed for up to 1 year in 54% of
patients treated with abatacept (vs 33% of patients
treated with placebo) and inhibition of joint damage
was maintained.17 These findings suggest that initi-
ating selectively modulating T cell therapy at an
early stage could alter the course of RA.
The objective of this substudy of the AGREE
(Abatacept trial to Gauge Remission and joint damage
progression in methotrexate-naive patients with Early
Erosive rheumatoid arthritis) trial6 was to evaluate the
impact on disease activity of reducing the dose of intra-
venous abatacept from the approved monthly dose of
∼10 mg/kg to ∼5 mg/kg, in patients who had achieved
disease activity score (DAS)28 (erythrocyte sedimenta-
tion rate, ESR) of <2.6 at year 2 of treatment.
PATIENTS AND METHODS
Patients
Of the 87 sites that had enrolled patients in the initial
2-year, randomised AGREE study, 35 sites enrolled
patients in the AGREE substudy. The AGREE study
included patients who were MTX-naïve with early
(≤2 years), erosive, seropositive RA.6 To enter the
substudy, patients were required to have achieved
DAS28 (ESR) <2.6 at year 2 (day 701) of the main
study and to reaffirm their informed consent.
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Study design
The substudy was a 12-month, multicentre, randomised, double-
blind, two-arm, parallel-dosing study (NCT00989235). Patients
were randomised (1:1) to receive intravenous abatacept monthly
at doses of ∼10 mg/kg or ∼5 mg/kg based on weight range. No
dose adjustments were allowed. Concomitant medication was
kept stable and selected conventional synthetic DMARDs were
permitted. If a patient had an increase in disease activity, con-
comitant DMARDs or corticosteroids could be modified or the
patient could discontinue the double-blind study and resume
open-label intravenous abatacept ∼10 mg/kg.
DAS28 (ESR) was used for enrolment criteria, whereas
DAS28 (C reactive protein, CRP) was used for all disease activ-
ity assessments, including baseline measurements (to reflect the
AGREE study).
Assessments
The primary end point was the time to disease relapse (defined
as additional DMARD required, or ≥two courses of high-dose
steroids, or requirement for open-label intravenous abatacept
∼10 mg/kg, or DAS28 (CRP) ≥3.2 at two consecutive visits) and
was presented as Kaplan-Meier cumulative percentage of events
of disease relapse. Secondary end points included disease activ-
ity measured by DAS28 (CRP); proportion of patients who at
any time modified therapy and/or had two consecutive DAS28
(CRP) scores ≥3.2 (therapy modification included additional
DMARD required, ≥two courses of high-dose steroids, and
return to open-label intravenous abatacept ∼10 mg/kg); propor-
tion of patients who lost remission status at any time (defined as
DAS28 (CRP) ≥2.6); safety and tolerability; quarterly
steady-state trough serum concentrations (Cmin) of abatacept;
and quarterly immunogenicity (antiabatacept antibodies).
Physical function was determined quarterly using the Health
Assessment Questionnaire–Disability Index (HAQ-DI).
Statistical analysis
A specific power calculation was not performed. All patients
receiving at least one dose of abatacept were evaluated monthly.
The time to disease relapse was evaluated in a Kaplan-Meier
curve (Cox proportional hazards model); mean changes in
DAS28 (CRP) and HAQ-DI from baseline were determined
together with 95% CIs for adjusted treatment difference; last
observation carried forward method was used to impute missing
day 365 values; and scores and/or missing values for patients
who modified therapy were imputed using the last assessment
prior to the first occurrence of intervention therapy. The pro-
portion of patients who reached each relapse component or
who lost remission status were evaluated using 95% CI for treat-
ment difference; pharmacokinetics were evaluated using geo-
metric mean and percentage coefficient of variation for Cmin.
RESULTS
Patient disease characteristics are summarised in table 1. Mean
DAS28 (CRP) at baseline was 2.1 in each group. Over the
12-month follow-up period, three patients discontinued treat-
ment in the ∼10 mg/kg group compared with five patients in
the ∼5 mg/kg group; of these, one patient discontinued due to
lack of efficacy (abatacept ∼10 mg/kg group) and one patient
discontinued due to an adverse event (abatacept ∼5 mg/kg
group, endocarditis; figure 1).
The same number of patients (n=4) in each group returned to
open-label intravenous abatacept ∼10 mg/kg (table 2). Of the four
patients in the ∼5 mg/kg group who returned to open-label abata-
cept ∼10 mg/kg, three had regained DAS28 (CRP) <2.6 by month
12. Therapy was modified by more patients in the ∼5 mg/kg
group than in the ∼10 mg/kg group; no patients in either group
required concomitant high-dose corticosteroids (table 2). The
Kaplan-Meier curves of relapse over time (figure 2) and the pro-
portions of patients experiencing relapse over 12 months were
similar in both groups (table 2; ∼10 mg/kg vs ∼5 mg/kg; HR:
0.87; 95% CI 0.45 to 1.69).
Changes in DAS28 (CRP) and the proportions of patients
who lost DAS28 (CRP)-defined remission status were similar
between groups at month 12 (table 2). Changes in the HAQ-DI
score from baseline to month 12 were −0.07 in the ∼10 mg/kg
group and 0.06 in the ∼5 mg/kg group.
Safety results were comparable between the two dosing
groups. One death occurred (∼5 mg/kg group, acute cardiopul-
monary failure). Serious adverse events were reported in three
patients in the ∼10 mg/kg group (claw toe, appendicitis, pleurisy)
and in three patients in the ∼5 mg/kg group (RA flare, uncon-
trolled diabetes mellitus, acute renal insufficiency, leucopenia,
neutropenia and endocarditis (all in the same patient); osteoarth-
ritis and acute cardiopulmonary insufficiency (in one patient);
and RA flare). Infections were observed in 22 (37.9%) patients in
the ∼10 mg/kg group and 13 (26.0%) in the ∼5 mg/kg group.
Table 1 Patient baseline demographics and disease characteristics
Double-blind abatacept ∼10 mg/kg Double-blind abatacept ∼5 mg/kg Total
Number of patients treated 58 50 108
Age, years, mean (SD) 50.1 (11.5) 51.1 (13.4) 50.6 (12.3)
Female 44 (75.9) 41 (82.0) 85 (78.7)
White 49 (84.5) 46 (92.0) 95 (88.0)
Duration of RA,* mean (SD) 2.2 (0.4) 2.4 (0.5) 2.3 (0.5)
TJC, mean (SD) 1.4 (2.5) 1.1 (1.5) 1.3 (2.1)
SJC, mean (SD) 0.7 (1.4) 0.5 (1.1) 0.6 (1.2)
HAQ-DI, mean (SD) 0.5 (0.5) 0.6 (0.6) 0.6 (0.5)
Patient global assessment, mean (SD) 14.3 (16.8) 16.3 (12.9) 15.3 (15.0)
DAS28 (CRP), mean (SD) 2.1 (0.6) 2.1 (0.6) 2.1 (0.6)
CRP mg/dL, mean (SD) 0.5 (0.6) 0.5 (0.5) 0.5 (0.5)
Data are n (%), unless otherwise indicated.
*At the start of the sub-study.
CRP, C reactive protein; DAS, disease activity score; HAQ-DI, Health Assessment Questionnaire–Disability Index; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint
count.
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Peri-infusional reactions (all mild-to-moderate) were seen in five
and two patients, respectively. Two autoimmune events (episcler-
itis and Sjögren’s syndrome) and one mild infusional reaction
occurred (all in the ∼5 mg/kg group).
In the reduced abatacept dose group (∼5 mg/kg), consistent
Cmin was achieved between month 3 and month 6, with geomet-
ric mean Cmin ranging from 8.8 mg/mL to 12.0 mg/mL; the
range was 20.3 mg/mL to 24.1 mg/mL during follow-up in the
∼10 mg/kg abatacept group. Six of 105 (5.7%) patients devel-
oped positive responses for antiabatacept antibodies assay (four
in the ∼10 mg/kg group; two in the ∼5 mg/kg group); five were
positive for anticytotoxic T lymphocyte antigen 4 and possibly
immunoglobulin antibodies and one was positive for immuno-
globulin and/or junction region antibodies.
DISCUSSION
Data from this substudy in MTX-naïve patients with early RA
and poor prognosis, who had achieved DAS28 (ESR) <2.6 after
2 years of monthly abatacept (∼10 mg/kg) plus MTX in the
AGREE trial, demonstrate that reduced disease activity can be
maintained in some patients after reducing the dose of abatacept
from the approved monthly intravenous dose of ∼10 mg/kg to
∼5 mg/kg. There was no significant increase in disease activity,
and few patients required additional DMARDs or return to
open-label ∼10 mg/kg abatacept. As such, the findings support
those from the PRIZE study, with most patients maintaining
remission following biological dose reduction.14
Systemic exposure was approximately 50% lower in the abata-
cept ∼5 mg/kg group compared with the ∼10 mg/kg group,
which is consistent with the linear pharmacokinetic profile of
abatacept.18 Published steady-state mean (range) Cmin values,
following administration of the approved monthly intravenous
dose, are 24 (1–66) mg/mL.19 Despite lower exposure in the
∼5 mg/kg group, approximately 50% of patients maintained
Cmin at ∼10 mg/mL (associated with maximal inhibition of T cell
proliferation and cytokine production).20 Lower drug exposure
in the ∼5 mg/kg group did not appear to increase the risk of
immunogenicity. In general, the number and type of safety
events were as expected based on previous reports,21 and did
not differ between groups.
These findings should be interpreted with some caution
owing to the small sample size and the fact that the population
included only those patients with early RA who had achieved
remission after 2 years of treatment with abatacept (∼10 mg/kg).
Figure 1 Patient disposition. *Open-label ∼10 mg/kg abatacept. AE, adverse event.
Table 2 Summary of efficacy results
Double-blind abatacept ∼10 mg/kg
(n=58)
Double-blind abatacept ∼5 mg/kg
(n=50)
Patients experiencing disease relapse 18 (31.0) 17 (34.0)
Patients with two consecutive DAS28 (CRP) scores ≥3.2 13 (22.4) 11 (22.0)
Patients with modified therapy 6 (10.3) 9 (18.0)
Additional DMARD 2 (3.4) 6 (12.0)
High-dose steroids 0 0
Return to open-label ∼10 mg/kg abatacept 4 (6.9) 4 (8.0)
Patients losing remission status* 31 (53.4) 32 (64.0)
DAS28 (CRP) mean change from baseline (SE)† 0.27 (0.10) 0.25 (0.11)
Physical function (HAQ-DI) mean change from baseline (SE)† –0.07 (0.04) 0.06 (0.05)
Data are n (%), unless otherwise indicated.
*Defined as DAS28 (CRP) ≥2.6 at any time point.
†LOCF analysis: missing day 365 values were imputed using the LOCF method. For patients with modified therapy, scores and/or missing values were imputed using the last assessment
prior to the first occurrence of intervention therapy. N values for DAS28 (CRP) mean changes were 50 and 43, and for HAQ-DI were 54 and 45, for abatacept ∼10 mg/kg and ∼5 mg/
kg, respectively.
CRP, C reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire–Disability Index; LOCF, last observation
carried forward.
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In addition, this study was designed before acceptance of the
more stringent remission criteria proposed by the American
College of Rheumatology and European League Against
Rheumatism; the DAS28 (CRP) criteria were used in the sub-
study for consistency with the original AGREE study primary
end point. Another limitation was the use of two different
DAS28 measures: DAS28 (ESR) to aid rapid determination of
patient eligibility, and DAS28 (CRP) for all other disease activity
assessment.
In summary, considering the potential to alter the course of
disease in some patients with early RA, along with the safety
and health economic benefits in avoiding unnecessary drug
exposure, timely induction of biological agents (preferably in
combination with MTX), followed by dose reduction, might be
a therapeutic option in patients with early RA who have
achieved DAS28 <2.6, and deserves further investigation.
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